公开(公告)号：WO2016063204A1

公开(公告)日：2016-04-28

申请号：PCT/IB2015/058048

申请日：2015-10-19

Applicant: NESTEC S.A.

Inventor： SINGH, Sharat ,  KONDRAGUNTA, Venkateswarlu

IPC: G01N33/50 ,  G01N33/564

CPC classification number: G01N33/564 ,  G01N33/5091 ,  G01N33/6869 ,  G01N33/94 ,  G01N2333/5421 ,  G01N2333/5434 ,  G01N2800/065 ,  G01N2800/52

Abstract: In some aspects, the present invention provides methods for predicting whether a subject will develop autoantibodies to an anti-TNFα drug during the course of anti- TNFα drug therapy. In other aspects, the present invention provides methods for predicting the level of an anti-TNFα drug in a subject during the course of anti-TNFα drug therapy. Systems for predicting anti-TNFα drug levels and the likelihood of autoantibody formation during the course of anti-TNFα drug therapy are also provided herein. The present invention further provides methods for predicting a clinical outcome (e.g., endoscopic response) of a subject on anti-TNFα drug therapy.

Abstract translation: 在一些方面，本发明提供了在抗TNFα药物治疗过程中预测受试者是否会向抗TNFα药物发展自身抗体的方法。 在其他方面，本发明提供了在抗TNFα药物治疗过程中预测受试者中抗TNFα药物水平的方法。 本文还提供了在抗TNFα药物治疗过程中预测抗TNFα药物水平和自身抗体形成的可能性的系统。 本发明还提供了用于预测受试者对抗TNFα药物治疗的临床结果（例如内镜反应）的方法。

公开(公告)号：WO2018220588A1

公开(公告)日：2018-12-06

申请号：PCT/IB2018/053923

申请日：2018-05-31

Applicant: NESTEC S.A.

Inventor： JAIN, Anjali ,  KONDRAGUNTA, Venkateswarlu ,  HALE, Michael

IPC: G01N33/68 ,  G01N33/564

Abstract: The present disclosure provides methods for assessing mucosal healing in a patient with Crohn's Disease. The methods include detecting expression levels of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient. The present disclosure also provides kits that include two or more binding partners, each or which is capable of binding a different analyte measured in the disclosed mucosal healing assessment methods.

公开(公告)号：WO2016088068A1

公开(公告)日：2016-06-09

申请号：PCT/IB2015/059303

申请日：2015-12-02

Applicant: NESTEC S.A.

Inventor： SINGH, Sharat ,  JAIN, Anjali ,  KONDRAGUNTA, Venkateswarlu

IPC: G01N33/564 ,  G01N33/68

CPC classification number: G01N33/564 ,  G01N33/15 ,  G01N33/48 ,  G01N33/68 ,  G01N2333/70546 ,  G01N2800/065 ,  G01N2800/52

Abstract: The present invention provides methods for predicting whether an individual having inflammatory bowel disease (IBD) is likely to respond to vedolizumab treatment. Also provided are methods for predicting whether an individual with IBD such as Crohn's disease or ulcerative colitis will develop autoantibodies against vedolizumab. The present invention also provides a treatment regimen for an IBD patient which includes measuring the level of one or more predictive markers of response to vedolizumab prior to administering the anti-α4β7 integrin drug.

Abstract translation: 本发明提供了用于预测具有炎症性肠病（IBD）的个体是否可能对vedolizumab治疗作出反应的方法。 还提供了用于预测具有IBD的个体（例如克罗恩病或溃疡性结肠炎）是否会发展针对vedolizumab的自身抗体的方法。 本发明还提供了IBD患者的治疗方案，其包括在施用抗α4β7整联蛋白药物之前测量对vedolizumab的一种或多种预测标记物的应答水平。